Brexpiprazole, marketed as Rexulti, was developed as a refinement of aripiprazole — a partial dopamine agonist with adjustments to the receptor binding profile aimed at smoothing out two of aripiprazole's most common complaints: akathisia and insomnia. The clinical data largely support that goal. Brexpiprazole tends to be calmer and less activating than aripiprazole. The trade-off is that it tends to produce slightly more sedation and weight gain. Whether that trade is favourable depends on what you didn't tolerate the first time.
Brexpiprazole shares aripiprazole's partial-agonist mechanism but with less akathisia and insomnia, slightly more weight gain and sedation, and a similar boxed-warning class profile.
Akathisia: less common but not gone
The most clinically meaningful difference between brexpiprazole and aripiprazole is the rate of akathisia. In pivotal trials and pooled analyses summarised in The Journal of Clinical Psychiatry, akathisia rates with brexpiprazole at standard schizophrenia doses are typically 5–8%, compared with 15–20% on aripiprazole. That is a real reduction.
It is not zero, however. A meaningful minority of patients still experience akathisia on brexpiprazole, and the management is the same: dose adjustment, beta-blocker addition, or short-term benzodiazepine support. See our akathisia guide.
Sedation
Brexpiprazole is moderately more sedating than aripiprazole. Many patients describe it as "calming" rather than "drugged," which can be a benefit — particularly for patients whose insomnia or anxiety on aripiprazole was the deal-breaker. Others find it too sedating and prefer the activating profile of its predecessor.
Weight and metabolic effects
Brexpiprazole produces slightly more weight gain than aripiprazole on average, though both are at the lighter end of the antipsychotic spectrum. Average gains in trials have been in the 1–3 kg range over the first year, with the usual long tail of patients who gain considerably more. Metabolic effects on glucose and lipids are modest.
Standard metabolic monitoring applies. See our weight gain management guide and metabolic syndrome explainer.
Impulse-control concerns
Brexpiprazole, like aripiprazole and cariprazine, carries the FDA's class warning about pathological gambling, hypersexuality, compulsive shopping, and binge eating. The mechanism is thought to involve dopamine receptor activity in reward pathways. Cases are uncommon but can be devastating; the practical advice is the same as for aripiprazole — patients and families should know to look for and report any new compulsive behaviour patterns.
You notice new urges to gamble, spend money compulsively, binge-eat, or pursue sexual activity in ways that feel out of character.
Prolactin
Like aripiprazole, brexpiprazole tends to be prolactin-sparing or even prolactin-lowering. This makes it a reasonable choice for patients who developed symptomatic hyperprolactinemia on risperidone or paliperidone.
Movement effects
Beyond akathisia, brexpiprazole can cause parkinsonism, dystonia, and (with long-term use) tardive dyskinesia. Rates are generally low and similar to other partial agonists. Periodic AIMS screening is standard practice.
Other commonly reported effects
- Headache — particularly during titration
- Nausea — usually settles within a week or two
- Constipation — usually mild; respond to hydration and fibre
- Dizziness and orthostatic hypotension — modest
Approved uses
Brexpiprazole is FDA-approved for:
- Schizophrenia in adults
- Adjunctive treatment of major depressive disorder
- Agitation associated with Alzheimer's disease (added in 2023)
The Alzheimer's-agitation indication is notable because it remains the only FDA-approved drug for this purpose, but it carries the same class boxed warning about increased mortality in elderly patients with dementia-related psychosis. The decision to use it in dementia involves a careful balance of severe agitation distress against that risk.
Boxed warnings
Like all antipsychotics, brexpiprazole carries:
- Increased mortality in elderly patients with dementia-related psychosis
- Increased risk of suicidal thoughts in young adults treated for depression
When to call the prescriber
- Restlessness or unable to sit still
- Significant weight gain (more than 5% of starting body weight in three months)
- New compulsive urges
- New tremor, stiffness, or involuntary movements
- Persistent nausea or constipation
- Mood changes, particularly worsening depression or new suicidal thoughts
Switching considerations
Patients commonly switch to brexpiprazole from aripiprazole because of akathisia or insomnia. Patients who don't tolerate brexpiprazole often consider:
- Cariprazine — also a partial agonist, with longer half-life
- Aripiprazole — back to the original, perhaps with better timing or dose
- Lurasidone — different mechanism, food-dependent, generally weight-light
- Lumateperone — newer, very metabolically light
Cost considerations
Brexpiprazole is still under patent in the United States (generic expected later in the decade), making it expensive. Patients without insurance coverage often find aripiprazole — now generic — much more affordable, even if the side effect trade is less favourable. Manufacturer assistance programs are available for those who qualify.
The bottom line
Brexpiprazole is a useful refinement of aripiprazole rather than a fundamentally different drug. It serves patients who responded to aripiprazole's mechanism but couldn't tolerate the activating side effects. For some patients, it is the difference between staying on a medication and discontinuing — which, given the consequences of relapse in schizophrenia, is no small thing.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.